Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 12, 2009 Brian Orelli	How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way.
Chemistry World May 19, 2008 Hepeng Jia	China's one stop research shop John Oyler has founded a string of startups in the US, but in 2005 he chose China as his base to launch BioDuro, a life sciences Contract Research Organisation.
BusinessWeek December 13, 2004 Bruce Einhorn	Go East, Big Pharma Drugmakers are expanding in China, but patents are still a worry.
Pharmaceutical Executive December 1, 2010 Zhu Shen	China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda
Chemistry World August 21, 2013 Phillip Broadwith	Two way traffic for Chinese drug licensing Chinese companies have trailed behind their Western counterparts in developing innovative new drugs. Very few of those inventions have been considered useful enough to be licensed by western companies. However, that appears to be changing.
The Motley Fool August 13, 2007 Andrew R. Vaino	Do You See What I WuXi? This Chinese biotech outsourcing firm recently went public and has lots of room to grow.
Pharmaceutical Executive September 1, 2008 Zhu Shen	Unleash the Dragon Concerns over quality? It's not stopping Big Pharma outsourcing and venture capital.
Chemistry World July 15, 2008 Hepeng Jia	Testing Times for New Liver Drug AstraZeneca is set to start clinical trials of a liver cancer drug developed for Chinese patients.
BusinessWeek September 4, 2008 Pete Engardio	Chinese Scientists Build Big Pharma Back Home In a reverse migration, U.S.-trained scientists are setting up biotech startups, contract-research companies, and university labs on the mainland.
Chemistry World August 23, 2012 Simon Campbell	Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth.
Pharmaceutical Executive December 1, 2011 George Baeder	China's Future in Bioscience Will big investments in infrastructure carry the day in positioning China as a global drug innovation powerhouse?
Chemistry World October 28, 2014 Hepeng Jia	China's science academy launches new reform drive The Chinese Academy of Sciences, the nation's largest research body, is to reshuffle its 100 plus research institutes and change the way it rewards scientists.
Chemistry World January 2008 Victoria Gill	A Model City Shanghai is being sculpted into the ideal of a modern Chinese city. It's also becoming China's center for scientific innovation.
Bio-IT World May 19, 2004 Barbara Depompa	Turning Sugar into Science The landmark building that housed the New England Confectionery Company in Revere, Mass. is being transformed into the new headquarters for the Novartis Institutes for BioMedical Research.
The Motley Fool December 27, 2007 Brian Orelli	Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there.
Chemistry World June 2010	Column: In the pipeline Derek Lowe looks into his crystal ball to see what the future of medicinal chemistry might be
Chemistry World November 6, 2013 Laura Howes	Novartis to shut Horsham site Last year, the firm slammed the UK for the high cost of conducting clinical trials in the country, warning that business would leave unless more incentives were introduced to encourage firms to carry out R&D.
The Motley Fool March 30, 2011 Sean Williams	China Clamps Down on Drug Manufacturers These drug manufacturers could be feeling a pinch from new Chinese price caps.
Fast Company November 2010 Elizabeth Svoboda	The Myelin Repair Foundation Encourages Collaboration for a Cure Scientists in their labs. Big Pharma in pursuit of the next blockbuster. An innovative foundation brings them together to speed up the discovery of multiple-sclerosis drugs.
Pharmaceutical Executive October 1, 2006 Ray Hill	China: Big Rewards. Bigger Risks? The world's fastest growing pharmaceutical market may one day be the largest. Breaking in could be industry's greatest challenge.
Chemistry World September 3, 2014 Rajesh Parishwad	Piramal exits drug discovery in India India's Piramal Enterprises is exiting its early-stage drug discovery research and focusing on late clinical development, along with its core areas such as generics and contract research services.
Chemistry World June 2011	Column: In the pipeline Chemists are human. Humans are hierarchical. Therefore...well, therefore, you'll find a number of different roles and levels for scientists in a drug company's labs. Here's a rough ordering, from least experienced to most.
Bio-IT World November 2006 Kevin Davies	Building a Bridge Over Pharma with IT More than 100 enthusiastic delegates bridging the full breadth of the drug development pipeline gathered recently for the second annual Bridging Pharma and IT conference. Here are some highlights.
The Motley Fool January 20, 2005 Stephen D. Simpson	Novartis Posts a Swiss Miss The Swiss drug giant has a strong pipeline, but moderate growth and high valuation suggest little room for error.
Bio-IT World November 2006 Kevin Davies	Jubilant Curries Favor with BioPharma The explosion of drug discovery and development operations in India is epitomized by the success of several companies. Quietly building on a decade of experience in computational and bio-IT fields, JBL is rapidly pushing into a suite of drug discovery and development activities.
Chemistry World October 11, 2007 Hepeng Jia	China's Drug Industry Set to Take Off Producing cheap drugs for the developing world could allow Chinese pharmaceutical firms to capture a bigger share of the international market, industry experts suggest.
Pharmaceutical Executive June 1, 2005 Jan Malek	When Two Heads are Better R&D president isn't one job-it's two. By appointing COOs for R&D with broad operational mandates, biotech and pharmaceutical companies can ensure that operational issues get the attention they urgently require.
Chemistry World April 2011	Molecular Obesity is Weighing Down Drug Discovery Medicinal chemistry's quest for potent drug candidates has resulted in molecules that are too large and too lipophilic for their own good.
The Motley Fool October 11, 2011 Cliff D'Arcy	AstraZeneca Loves This $100Bn Market The British pharma firm makes its largest-ever manufacturing investment -- in China.
Pharmaceutical Executive September 1, 2010	Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development.
The Motley Fool July 11, 2007 Brian Lawler	Not All Pharmaceutical Markets Are the Same The case of China's former FDA leader highlights the issues facing the country's pharmaceutical industry. Investors, take note.
BusinessWeek December 29, 2010 Kelley & Cortez	AstraZeneca's Risky Bet on Drug Discovery Instead of acquisitions and diversification, AstraZeneca is determined to find new pills in its own labs.
BusinessWeek May 28, 2007 Bruce Einhorn	The Rush To Test Drugs In China Despite ethical concerns, Big Pharma is recruiting more patients for clinical trials in China.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
Chemistry World June 11, 2008 James Mitchell Crow	GSK Job Cuts Hit Chemists GlaxoSmithKline is cutting the jobs of hundreds of scientists as it restructures its drug R&D operations.
Chemistry World March 2011	Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations
The Motley Fool June 7, 2004 Brian Gorman	Novartis Nabs Sabex Novartis' purchase gives it a lifeline to the generics market.
Chemistry World December 1, 2014 Derek Lowe	Progress at the pace of the slowest Chemistry is a means to an end in drug research, not an end in itself, and that can take some getting used to. It's worth thinking about where chemistry fits into the big picture.
Information Today October 22, 2009	New Network for Chinese Researchers With a goal of reducing the barriers separating Chinese researchers from their counterparts in the U.S. and Europe, Anianet announced the launch of the Anianet professional network
The Motley Fool February 26, 2010 Brian Orelli	Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue.
The Motley Fool October 23, 2006 Brian Lawler	No Slowing Novartis The Swiss pharmaceutical company shows strength in nearly all its divisions. Novartis looks like a good investment for risk-adverse investors searching for a large-cap pharma stock.
The Motley Fool February 9, 2007 Will Frankenhoff	I Love Chinese Stocks Given the overall strength of the Chinese economy and the attractive valuations of many "red-chip" companies, investors should consider opening their hearts to this emerging market's potential rewards, and adding to their positions during any weakness.
The Motley Fool May 5, 2004 Brian Gorman	Albany Molecular Gets Out-Outsourced Albany Molecular Research, provider of chemistry services to biotech and pharmaceutical clients, is suffering from the loss of business to low-cost competitors overseas.
Chemistry World November 10, 2015 Hepeng Jia	China's first science Nobel prize exposes anxiety on research Artemisinin saves tens of thousands of lives every year. The story of its discovery has been debated for decades in China. The awarding of the medicine Nobel prize has only served to reopen old wounds.
Bio-IT World October 14, 2004 Michael Greeley	Go East Business is great in China, and the government is strongly encouraging the local biotech industry.
The Motley Fool November 6, 2006 Brian Gorman	Novartis' China Gambit Novartis probably won't get any near-term dividend from its China investment, but the nation is too big to ignore. Investors, take note.
Bio-IT World September 2006 Mike May	Working Out the Flow Better management of workflow issues in biotech and pharma could change fundamental aspects of these sciences in the near future.
The Motley Fool December 21, 2010 Brian Orelli	4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday.
Bio-IT World March 8, 2005 Kevin Davies	InforSense Approach to Data Sharing CEO Yike Guo discusses Shanghai's giant grid computing project to link scientists.
Pharmaceutical Executive September 1, 2008 Patrick Clinton	Attack of the Junk The United States makes the best medicines in the world. In days to come, that could be a problem.